- Investing Ideas
- /
- Hong Kong Biotech Breakthroughs
Hong Kong Biotech Breakthroughs
Results
5
5 companies
RemeGen
Market Cap: HK$21.5b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$26.50
7D
19.1%
1Y
-9.6%
Akeso
Market Cap: HK$77.1b
A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
9926
HK$85.90
7D
21.1%
1Y
88.4%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$70.2b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally.
6990
HK$309.00
7D
7.3%
1Y
107.1%
Everest Medicines
Market Cap: HK$19.0b
A biopharmaceutical company, engages in discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$58.45
7D
8.4%
1Y
154.1%
CanSino Biologics
Market Cap: HK$11.9b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$33.65
7D
-1.9%
1Y
97.0%